COVID-19 Impact on Global Pharmaceutical Products and CMO Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Pharmaceutical Products and CMO Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Pharmaceutical Products and CMO Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Active Pharmaceutical Ingredient (API)
  • 1.4.3 Finished Dosage Form (FDF)
  • 1.4.4 Pharmaceutical Packaging
• 1.5 Market by Application
  • 1.5.1 Global Pharmaceutical Products and CMO Market Share by Application: 2020 VS 2026
  • 1.5.2 Specialty/Midsize
  • 1.5.3 Generics
  • 1.5.4 Big Pharma
  • 1.5.5 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Pharmaceutical Products and CMO Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Pharmaceutical Products and CMO Industry
    • 1.6.1.1 Pharmaceutical Products and CMO Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Pharmaceutical Products and CMO Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Pharmaceutical Products and CMO Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Pharmaceutical Products and CMO Market Perspective (2015-2026)
• 2.2 Pharmaceutical Products and CMO Growth Trends by Regions
  • 2.2.1 Pharmaceutical Products and CMO Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Pharmaceutical Products and CMO Historic Market Share by Regions (2015-2020)
  • 2.2.3 Pharmaceutical Products and CMO Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Pharmaceutical Products and CMO Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Pharmaceutical Products and CMO Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Pharmaceutical Products and CMO Players by Market Size
  • 3.1.1 Global Top Pharmaceutical Products and CMO Players by Revenue (2015-2020)
  • 3.1.2 Global Pharmaceutical Products and CMO Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Pharmaceutical Products and CMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Pharmaceutical Products and CMO Market Concentration Ratio
  • 3.2.1 Global Pharmaceutical Products and CMO Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Pharmaceutical Products and CMO Revenue in 2019
• 3.3 Pharmaceutical Products and CMO Key Players Head office and Area Served
• 3.4 Key Players Pharmaceutical Products and CMO Product Solution and Service
• 3.5 Date of Enter into Pharmaceutical Products and CMO Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Pharmaceutical Products and CMO Historic Market Size by Type (2015-2020)
• 4.2 Global Pharmaceutical Products and CMO Forecasted Market Size by Type (2021-2026)

5 Pharmaceutical Products and CMO Breakdown Data by Application (2015-2026)

• 5.1 Global Pharmaceutical Products and CMO Market Size by Application (2015-2020)
• 5.2 Global Pharmaceutical Products and CMO Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Pharmaceutical Products and CMO Market Size (2015-2020)
• 6.2 Pharmaceutical Products and CMO Key Players in North America (2019-2020)
• 6.3 North America Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 6.4 North America Pharmaceutical Products and CMO Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Pharmaceutical Products and CMO Market Size (2015-2020)
• 7.2 Pharmaceutical Products and CMO Key Players in Europe (2019-2020)
• 7.3 Europe Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 7.4 Europe Pharmaceutical Products and CMO Market Size by Application (2015-2020)

8 China

• 8.1 China Pharmaceutical Products and CMO Market Size (2015-2020)
• 8.2 Pharmaceutical Products and CMO Key Players in China (2019-2020)
• 8.3 China Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 8.4 China Pharmaceutical Products and CMO Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Pharmaceutical Products and CMO Market Size (2015-2020)
• 9.2 Pharmaceutical Products and CMO Key Players in Japan (2019-2020)
• 9.3 Japan Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 9.4 Japan Pharmaceutical Products and CMO Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Pharmaceutical Products and CMO Market Size (2015-2020)
• 10.2 Pharmaceutical Products and CMO Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 10.4 Southeast Asia Pharmaceutical Products and CMO Market Size by Application (2015-2020)

11 India

• 11.1 India Pharmaceutical Products and CMO Market Size (2015-2020)
• 11.2 Pharmaceutical Products and CMO Key Players in India (2019-2020)
• 11.3 India Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 11.4 India Pharmaceutical Products and CMO Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Pharmaceutical Products and CMO Market Size (2015-2020)
• 12.2 Pharmaceutical Products and CMO Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Pharmaceutical Products and CMO Market Size by Type (2015-2020)
• 12.4 Central & South America Pharmaceutical Products and CMO Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Catalent
  • 13.1.1 Catalent Company Details
  • 13.1.2 Catalent Business Overview and Its Total Revenue
  • 13.1.3 Catalent Pharmaceutical Products and CMO Introduction
  • 13.1.4 Catalent Revenue in Pharmaceutical Products and CMO Business (2015-2020))
  • 13.1.5 Catalent Recent Development
• 13.2 DPx
  • 13.2.1 DPx Company Details
  • 13.2.2 DPx Business Overview and Its Total Revenue
  • 13.2.3 DPx Pharmaceutical Products and CMO Introduction
  • 13.2.4 DPx Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.2.5 DPx Recent Development
• 13.3 Lonza
  • 13.3.1 Lonza Company Details
  • 13.3.2 Lonza Business Overview and Its Total Revenue
  • 13.3.3 Lonza Pharmaceutical Products and CMO Introduction
  • 13.3.4 Lonza Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.3.5 Lonza Recent Development
• 13.4 Piramal Healthcare
  • 13.4.1 Piramal Healthcare Company Details
  • 13.4.2 Piramal Healthcare Business Overview and Its Total Revenue
  • 13.4.3 Piramal Healthcare Pharmaceutical Products and CMO Introduction
  • 13.4.4 Piramal Healthcare Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.4.5 Piramal Healthcare Recent Development
• 13.5 Aenova
  • 13.5.1 Aenova Company Details
  • 13.5.2 Aenova Business Overview and Its Total Revenue
  • 13.5.3 Aenova Pharmaceutical Products and CMO Introduction
  • 13.5.4 Aenova Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.5.5 Aenova Recent Development
• 13.6 Jubilant
  • 13.6.1 Jubilant Company Details
  • 13.6.2 Jubilant Business Overview and Its Total Revenue
  • 13.6.3 Jubilant Pharmaceutical Products and CMO Introduction
  • 13.6.4 Jubilant Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.6.5 Jubilant Recent Development
• 13.7 Famar
  • 13.7.1 Famar Company Details
  • 13.7.2 Famar Business Overview and Its Total Revenue
  • 13.7.3 Famar Pharmaceutical Products and CMO Introduction
  • 13.7.4 Famar Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.7.5 Famar Recent Development
• 13.8 Boehringer Ingelheim
  • 13.8.1 Boehringer Ingelheim Company Details
  • 13.8.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  • 13.8.3 Boehringer Ingelheim Pharmaceutical Products and CMO Introduction
  • 13.8.4 Boehringer Ingelheim Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.8.5 Boehringer Ingelheim Recent Development
• 13.9 Fareva Holding
  • 13.9.1 Fareva Holding Company Details
  • 13.9.2 Fareva Holding Business Overview and Its Total Revenue
  • 13.9.3 Fareva Holding Pharmaceutical Products and CMO Introduction
  • 13.9.4 Fareva Holding Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.9.5 Fareva Holding Recent Development
• 13.10 AbbVie
  • 13.10.1 AbbVie Company Details
  • 13.10.2 AbbVie Business Overview and Its Total Revenue
  • 13.10.3 AbbVie Pharmaceutical Products and CMO Introduction
  • 13.10.4 AbbVie Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 13.10.5 AbbVie Recent Development
• 13.11 Nipro Corp
  • 10.11.1 Nipro Corp Company Details
  • 10.11.2 Nipro Corp Business Overview and Its Total Revenue
  • 10.11.3 Nipro Corp Pharmaceutical Products and CMO Introduction
  • 10.11.4 Nipro Corp Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.11.5 Nipro Corp Recent Development
• 13.12 Vetter
  • 10.12.1 Vetter Company Details
  • 10.12.2 Vetter Business Overview and Its Total Revenue
  • 10.12.3 Vetter Pharmaceutical Products and CMO Introduction
  • 10.12.4 Vetter Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.12.5 Vetter Recent Development
• 13.13 Sopharma
  • 10.13.1 Sopharma Company Details
  • 10.13.2 Sopharma Business Overview and Its Total Revenue
  • 10.13.3 Sopharma Pharmaceutical Products and CMO Introduction
  • 10.13.4 Sopharma Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.13.5 Sopharma Recent Development
• 13.14 Mylan (DPT Laboratories)
  • 10.14.1 Mylan (DPT Laboratories) Company Details
  • 10.14.2 Mylan (DPT Laboratories) Business Overview and Its Total Revenue
  • 10.14.3 Mylan (DPT Laboratories) Pharmaceutical Products and CMO Introduction
  • 10.14.4 Mylan (DPT Laboratories) Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.14.5 Mylan (DPT Laboratories) Recent Development
• 13.15 Recipharm
  • 10.15.1 Recipharm Company Details
  • 10.15.2 Recipharm Business Overview and Its Total Revenue
  • 10.15.3 Recipharm Pharmaceutical Products and CMO Introduction
  • 10.15.4 Recipharm Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.15.5 Recipharm Recent Development
• 13.16 NextPharma Technologies
  • 10.16.1 NextPharma Technologies Company Details
  • 10.16.2 NextPharma Technologies Business Overview and Its Total Revenue
  • 10.16.3 NextPharma Technologies Pharmaceutical Products and CMO Introduction
  • 10.16.4 NextPharma Technologies Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.16.5 NextPharma Technologies Recent Development
• 13.17 Dishman
  • 10.17.1 Dishman Company Details
  • 10.17.2 Dishman Business Overview and Its Total Revenue
  • 10.17.3 Dishman Pharmaceutical Products and CMO Introduction
  • 10.17.4 Dishman Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.17.5 Dishman Recent Development
• 13.18 Aesica
  • 10.18.1 Aesica Company Details
  • 10.18.2 Aesica Business Overview and Its Total Revenue
  • 10.18.3 Aesica Pharmaceutical Products and CMO Introduction
  • 10.18.4 Aesica Revenue in Pharmaceutical Products and CMO Business (2015-2020)
  • 10.18.5 Aesica Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer